🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Pharma Mar S.A.” Clear

  1. JNJ 67896062, Matching Placebo for Macitentan 75 mg, JNJ 67896062, Matching Placebo for Macitentan 37.5 mg, Opsumit 10 mg film-coated tablets, Matching Placebo for Macitentan 10 mg

    Pharma Mar S.A.

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  2. JNJ-67896049, JNJ-67896049, Opsumit 10 mg film-coated tablets, JNJ-68150420, JNJ-67896049

    Pharma Mar S.A.

    pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  3. JNJ-67896062, JNJ-67896062

    Pharma Mar S.A.

    Pediatric pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  4. JR-141

    Pharma Mar S.A.

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  5. JR-141, Elaprase 2 mg/ml concentrate for solution for infusion

    Pharma Mar S.A.

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  6. JX10, Jx10 placebo drug product is prepared as a sterile, lyophilized white to light yellow cake or powder for infusion.

    Pharma Mar S.A.

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  7. JZP258

    Pharma Mar S.A.

    Narcolepsy

    phase 3 small molecule active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab, Fianlimab

    Pharma Mar S.A.

    Melanoma

    phase 3 small molecule active

    1 trial

  9. KVD900, KVD900

    Pharma Mar S.A.

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  10. KVD900, KVD900

    Pharma Mar S.A.

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  11. Kreon 35 000 Ph. Eur. Lipase Einheiten, magensaftresistente Hartkapseln

    Pharma Mar S.A.

    Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreatectomy with Pancreatic Exocrine Insufficiency (PEI).

    phase 3 small molecule active

    1 trial

  12. LANSOPRAZOLE, LANSOPRAZOLE, Placebo to match lansoprazole high dose, Linaprazan glurate, Placebo to match Lansoprazole low dose, Placebo to match Linaprazan Glurate

    Pharma Mar S.A.

    Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

    phase 3 small molecule active

    1 trial

  13. LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion, Gemcitabine 2 g Powder for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Pharma Mar S.A.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  14. LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810

    Pharma Mar S.A.

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  15. LOMUSTINE, 4-L-[131I]iodo-phenylalanine, LOMUSTINE

    Pharma Mar S.A.

    Glioblastoma

    phase 3 small molecule active

    1 trial

  16. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Pharma Mar S.A.

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  17. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Pharma Mar S.A.

    Developmental and Epileptic Encephalopathies (DEEs)

    phase 3 small molecule active

    1 trial

  18. Lucerastat

    Pharma Mar S.A.

    Fabry disease

    phase 3 small molecule active

    1 trial

  19. METHOTREXATE, DEXAMETHASONE, DEXAMETHASONE, CYTARABINE, CYTARABINE, DASATINIB, PREDNISOLONE, CYTARABINE, PONATINIB, CYTARABINE, METHOTREXATE, METHOTREXATE, VINCRISTINE SULFATE, PREDNISOLONE, IMATINIB MESILATE, METHOTREXATE, DEXAMETHASONE, Olverembatinib, DEXAMETHASONE, VINCRISTINE SULFATE, DEXAMETHASONE, DASATINIB, DEXAMETHASONE

    Pharma Mar S.A.

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  20. MIDAZOLAM , PROPOFOL , ROCURONIUM BROMIDE , Cipepofol Injectable Emulsion, FENTANYL , SEVOFLURANE , PROPOFOL

    Pharma Mar S.A.

    General anaesthesia

    phase 3 small molecule active

    1 trial

  21. MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT

    Pharma Mar S.A.

    Anemia in subjects with sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  22. MITAPIVAT, MITAPIVAT, Placebo for AG-348, MITAPIVAT, MITAPIVAT

    Pharma Mar S.A.

    Pyruvate Kinase Deficiency

    phase 3 small molecule active

    1 trial

  23. MITAPIVAT, Placebo for MITAPIVAT, MITAPIVAT, MITAPIVAT, MITAPIVAT

    Pharma Mar S.A.

    Pyruvate Kinase Deficiency

    phase 3 small molecule active

    1 trial

  24. MITAPIVAT, Placebo for Mitapivat

    Pharma Mar S.A.

    Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources